---
title: "Scabies, who cares?"
# subtitle: "Doherty CSI: Clinical and Public Health Seminar"
author: Kylie Ainslie
format:
  revealjs: 
    mbed-resources: true  # uncomment for making a selfcontained html for sharing
    theme: default
    preview-links: auto
    pdf-max-pages-per-slide: 1
    output-file: ITG_presentation.html
logo: figures/UoM_Logo.svg
incremental: false
progress: true   # default
footer: Institute of Tropical Medicine Antwerp | 15 January 2026 | Kylie Ainslie
slide-number: false 
header-includes:
    - |
      <style>
        .reveal {
            font-size: 2.0em;  /* Adjust this value to make text smaller */
        }
      </style>
#title-slide-attributes: 
#  data-background-image: "resources_main/watercolour_sys02_img41_stormy-seas.jpg"
#  center-title-slide: false
engine: knitr
execute: 
  echo: false
  eval: false
#webr:
#  packages: ['ggplot2'] # Install R packages on document open
#  show-startup-message: false  # to keep the surprise :)
#filters: 
#  - timer
#  - webr
from: markdown+emoji
chalkboard: true       # comment out when wanting to make a selfcontained html
---

# What even is scabies?

## Sarcoptes *scabiei*

:::::::: columns
::::: {.column width="60%"}
::: {.fragment .fade-in fragment-index="1"}
-   Scabies is a disease caused by infestation of the skin with a microscopic mite.

    ::: {.fragment fragment-index="3"}
    -   a.k.a. the Itch or seven-year itch.
    :::

    ::: {.fragment fragment-index="4"}
    -   From the Latin *scabere*, meaning 'to scratch'.
    :::
:::

::: {.fragment .fade-in fragment-index="5"}
-   Symptoms are characterized by itchiness and rash at the site of infestation.
:::
:::::

:::: {.column width="40%"}
::: {.fragment .fade-in fragment-index="2"}
![Scabies mite. Image Credit: Aliaksei Marozau / Shutterstock.com](figures/scabies_mite.png){style="font-size: 0.7em;"}
:::
::::
::::::::

## How does scabies spread?

::: incremental
-   Direct, extended, skin-to-skin contact
-   Sharing clothing, towels, or bedding used by an infected person
    -   Less common
:::

# Do people still get scabies?

## Scabies Worldwide

:::::::: r-stack
:::::: {.fragment .fade-out fragment-index="3"}
::::: {style="text-align: left; width: 100%;"}
::: {.fragment .fade-in fragment-index="1"}
-   Scabies affects around 400 million people per year.
:::

::: {.fragment .fade-in fragment-index="2"}
-   Accounts for a large proportion of skin disease in many low- and middle-income countries
:::
:::::
::::::

::: {.fragment .fade-in fragment-index="3" style="text-align: center;"}
![Karimkhani et al. 2017. Lancet Infect. Dis. 17(12):1247 - 1254](figures/scabies_disease_burden_map2.png){width="100%" style="max-height: 95vh; object-fit: contain;"}
:::
::::::::

## Scabies in Europe (then)

::: incremental
-   Scabies infections were a common affliction in Europe in the late 1800s and early 1900s
    -   Highest incidence seen in 1918 and 1945.
:::

::: {.fragment style="text-align: center;"}
![Savin 2005. J R Soc Med; 98(3):124–129.4](figures/scabies_in_scotland.jpg){width="600" height="350"}
:::

## Scabies in Europe (now)

A rise in scabies cases has been observed through out Europe in recent years.

::::::: r-stack
::: {.fragment .fade-in-then-out style="text-align: center;"}
![Germany: Reichert et al. 2021. Emerg Infect Dis.;27(6):1693–1696.](figures/scabies_in_germany.jpg){width="100%" style="max-height: 500px; object-fit: contain;"}
:::

::: {.fragment .fade-in-then-out style="text-align: center;"}
![Croatia: Lugović-Mihić et al. 2020. Zdravstveno Varstvo; 59(4):264-272.](figures/scabies_in_croatia.jpeg){width="98%" style="max-height: 600px; object-fit: contain;"}
:::

::: {.fragment .fade-in-then-out style="text-align: center;"}
![Norway: Amato et al. 2019. Eurosurveillance; 24(23):pii=190020.](figures/scabies_in_norway.jpg){width="100%" style="max-height: 600px; object-fit: contain;"}
:::

::: {.fragment .fade-in-then-out style="text-align: center;"}
![Netherlands: van Deursen et al. 2022. PLoS One; 17:e0268865](figures/scabies_in_NL.png){width="98%" style="max-height: 600px; object-fit: contain;"}
:::

::: {.fragment .fade-in style="text-align: center;"}
![Belgium: Laisnez et al. 2025. Arch Public Health 83:197](figures/scabies_in_belgium.jpg){width="98%" style="max-height: 600px; object-fit: contain;"}
:::

:::::::

## Ok, so what's the big deal?

::: incremental
-   The global disease burden of scabies is low compared to other infectious diseases
-   Disease severity is also low
:::

## But...

During periods of high scabies prevalence:

::: incremental
-   Higher burden due to secondary infections
-   Increased pressure on healthcare systems
-   Negative economic impacts
-   Stigma-related delays in care-seeking
:::

# What can we do about it?

## What we need to know

::::: columns
::: {.column width="60%"}
:::

::: {.column width="40%"}
![Adapted from: Lehtinen et al. 2021. J. R. Soc. Interface.1820200756](figures/epi_intervals_schematic.jpeg){style="font-size: 0.7em;" fig-align="left" width="120%" height="120%"}
:::
:::::

## What we need to know

:::::: columns
:::: {.column width="60%"}
::: nonincremental
-   the **incubation period:** time from infection to symptom onset
:::
::::

::: {.column width="40%"}
![Adapted from: Lehtinen et al. 2021. J. R. Soc. Interface.1820200756](figures/incubation_period_schematic.jpeg){style="font-size: 0.7em;" fig-align="left" width="120%" height="120%"}
:::
::::::

## What we need to know

:::::: columns
:::: {.column width="60%"}
::: nonincremental
-   [**incubation period:** time from infection to symptom onset]{style="color:grey;"}
-   **generation time:** time between infection of an index case and a secondary case
:::
::::

::: {.column width="40%"}
![Adapted from: Lehtinen et al. 2021. J. R. Soc. Interface.1820200756](figures/generation_time.jpg){style="font-size: 0.7em;" fig-align="left" width="120%" height="120%"}
:::
::::::

## What we need to know

:::::: columns
:::: {.column width="60%"}
::: nonincremental
-   [**incubation period:** time from infection to symptom onset]{style="color:grey;"}
-   [**generation time:** time between infection of an index case and a secondary case]{style="color:grey;"}
-   **serial interval:** the time from onset of symptoms in an index case to the time of symptom onset in a secondary case
:::
::::

::: {.column width="40%"}
![Adapted from: Lehtinen et al. 2021. J. R. Soc. Interface.1820200756](figures/serial_interval_schematic.jpeg){style="font-size: 0.7em;" fig-align="left" width="120%" height="120%"}
:::
::::::

## What we need to know

:::::: columns
:::: {.column width="60%"}
::: nonincremental
-   [**incubation period:** time from infection to symptom onset]{style="color:grey;"}
-   [**generation time:** time between infection of an index case and a secondary case]{style="color:grey;"}
-   [**serial interval:** the time from onset of symptoms in an index case to the time of symptom onset in a secondary case]{style="color:grey;"}
-   **growth rate:** how quickly the numbers of infections are changing over time
:::
::::

::: {.column width="40%"}
![Picheira-Brown and Bentancor. 2021. Epidemics; 37:100486](figures/growth_rate.jpg){style="font-size: 0.7em;" fig-align="left" width="120%" height="120%"}
:::
::::::

## What we need to know

:::::: columns
:::: {.column width="60%"}
::: nonincremental
-   [**incubation period:** time from infection to symptom onset]{style="color:grey;"}
-   [**generation time:** time between infection of an index case and a secondary case]{style="color:grey;"}
-   [**serial interval:** the time from onset of symptoms in an index case to the time of symptom onset in a secondary case]{style="color:grey;"}
-   [**growth rate:** how quickly the numbers of infections are changing over time]{style="color:grey;"}
-   **reproduction number:** the average number of secondary cases resulting from one index case
:::
::::

::: {.column width="40%"}
![Adam Cole/NPR](figures/R0_comparison_chart.png){style="font-size: 0.7em;" fig-align="left" width="150%" height="150%"}
:::
::::::

## What we know

::: nonincremental
-   [**incubation period:** time from infection to symptom onset]{style="color:green;"}
-   [**generation time:** time between infection of an index case and a secondary case]{style="color:red;"}
-   [**serial interval:** the time from onset of symptoms in an index case to the time of symptom onset in a secondary case]{style="color:red;"}
-   [**growth rate:** how quickly the numbers of infections are changing over time]{style="color:red;"}
-   [**reproduction number:** the average number of secondary cases resulting from one index case]{style="color:red;"}
:::

## What we know

## What we know

:::::::::: columns
::::: {.column width="60%"}
::: {.fragment fragment-index="1"}
-   A series of studies in the 1940s form much of the basis of our current understanding of scabies transmission.
:::

::: {.fragment fragment-index="3"}
-   Incubation period
    -   4-6 weeks after primary infection
    -   24 hours after post-primary infection
:::
:::::

:::::: {.column width="40%"}
::::: r-stack
::: {.fragment fragment-index="2"}
![](figures/scabies_oxford_war_manual.png){fig-align="center"}
:::

::: {.fragment fragment-index="4"}
![](figures/mellanby_1944.png){width="600" height="100"}
:::
:::::
::::::
::::::::::

# Let's dive in!

## Our Roadmap

::: incremental
-   What is the timescale of a typical scabies transmission event?
-   How are the number of scabies cases changing over time?
-   How many people will a scabies case go on to infect?
-   How does scabies transmission change over time?
:::

## Our Roadmap

-   What is the timescale of a typical scabies transmission event?

## Serial Interval

::::::: columns
:::: {.column width="35%"}
::: {.fragment fragment-index="1"}
![Adapted from: Lehtinen et al. 2021. J. R. Soc. Interface.1820200756](figures/serial_interval_schematic.jpeg){style="font-size: 0.7em;" fig-align="left" width="120%" height="120%"}
:::
::::

:::: {.column width="65%"}
::: {.fragment fagment-index="2"}
![Date of symptom onset data from four scabies outbreaks.](figures/epi_curves_plot.png){style="font-size: 0.7em;" width="100%" height="100%"}
:::
::::
:::::::

## Serial Interval

::: incremental
-   We calculate the index case-to-case (ICC) interval for each person,
    -   **index case:** the person with the greatest value for number of days since symptom onset.
    -   **"secondary" cases:** have an ICC interval calculated as the number of days between their symptom onset day and the index case.
:::

## Serial Interval

::: nonincremental
-   We use a maximum likelihood framework to determine how likely each ICC interval can be attributed to each transmission route [- We then estimate serial interval using ICC intervals consistent with Primary-Secondary transmission]{style="color:white;"}
:::

![Vink et al. 2014. Am J Epidemiol; 180(9):865–875](figures/icc_interval.png)

## Serial Interval

::: nonincremental
-   We use a maximum likelihood framework to determine how likely each ICC interval can be attributed to each transmission route
    -   We then estimate serial interval using ICC intervals consistent with Primary-Secondary transmission
:::

![Vink et al. 2014. Am J Epidemiol; 180(9):865–875](figures/icc_interval_w_red_box.png)

## Serial Interval

![](figures/fig1.png){width="100%"}

::: {style="font-size: 0.5em;"}
Index-case-to-case (ICC) intervals (A-D) and comparison of serial interval estimates across studies (E). Red curves show fitted distributions.
:::

## Our Roadmap

-   [What is the timescale of a typical scabies transmission event?]{style="color:grey;"}
-   How are the number of scabies cases changing over time?

## Growth Rate

::: incremental
-   To determine how the number of scabies cases is changing each year in the Netherlands, we estimated the annual growth rate

-   **Estimated annual growth rate:** 0.25 (95% CI: 0.2, 0.3)
:::

::: fragment
![](figures/growth_rate_model_fit.png){width="60%"}
:::

## Our Roadmap

-   [What is the timescale of a typical scabies transmission event?]{style="color:grey;"}
-   [How are the number of scabies cases changing over time?]{style="color:grey;"}
-   How many people will a scabies case go on to infect?

## Basic Reproduction Number $R_0$

-   We can relate the growth rate to the basic reproduction number as $$R_0 = \exp(r*T – (1/2) r^2 s^2)$$
    -   $r$ is the annual growth rate,
    -   $T$ is the mean generation time (in years), and
    -   $s^2$ is the variance of the generation time distribution.

::: aside
**Assumption:** nearly everyone exposed has not been previously infected.
:::

## Basic Reproduction Number $R_0$

::: nonincremental
-   We can relate the growth rate to the basic reproduction number as $$R_0 = \exp(r*T – (1/2) r^2 s^2)$$
    -   $r$ is the annual growth rate,
    -   $T$ is the mean ~~generation time~~ serial interval (in years), and
    -   $s^2$ is the variance of the ~~generation time~~ serial interval distribution.
:::

-   This gives us an $R_0 = 1.09$ $(95\% CI: 1.07, 1.11)$

::: aside
**Assumption:** nearly everyone exposed has not been previously infected.
:::

## Our Roadmap

-   [What is the timescale of a typical scabies transmission event?]{style="color:grey;"}
-   [How are the number of scabies cases changing over time?]{style="color:grey;"}
-   [How many people will a scabies case go on to infect?]{style="color:grey;"}
-   How does scabies transmission change over time?

## Time-varying Reproduction Number $R_t$

![Incidence of scabies infections per 1000 people in the Netherlands by date of diagnosis.](figures/fig2.png){width="75%" height="75%" style="font-size: 0.7em;" fig-align="left"}

# Now what?

## Policy Implications

::: {.fragment fragment-index="1"}
**Controlling 8% of secondary infections prevents epidemic growth**
:::

:::::::: {style="font-size: 0.85em; margin-left: 2em;"}
::: {.fragment fragment-index="2"}
-   <i class="fas fa-bullhorn"></i> Educational campaign targeting high-risk groups
:::

::: {.fragment fragment-index="3"}
-   <i class="fas fa-user-md"></i> Enhanced GP training for rapid diagnosis
:::

::: {.fragment fragment-index="4"}
-   <i class="fas fa-clipboard-check"></i> Voluntary screening
:::

::: {.fragment fragment-index="5"}
-   <i class="fas fa-project-diagram"></i> Systematic contact tracing
:::

::: {.fragment fragment-index="6"}
-   <i class="fas fa-pills"></i> Targeted (voluntary) mass drug administration campaigns
:::
::::::::

## This is only the beginning

::: {.fragment fragment-index="1"}
**There is still a lot that we don't know**
:::

::: {.fragment fragment-index="2"}
-   Future research should prioritize three key areas:
:::

:::::: {style="font-size: 0.85em; margin-left: 2em;"}
::: {.fragment fragment-index="3"}
-   collecting transmission pair data
:::

::: {.fragment fragment-index="4"}
-   characterizing the delays between symptom onset and healthcare seeking
:::

::: {.fragment fragment-index="5"}
-   reproducing Mellanby’s 1944 incubation period estimates
:::
::::::

## Manuscript

![](figures/scabies_nat_comms.png){width="90%"}
![](figures/qrcode.png){.absolute bottom=10 right=10 width="200px"}

## Software

We developed an R package called [`mitey`](https://kylieainslie.github.io/mitey/){preview-link="true"}.

![](figures/mitey_hex_superman.png){width="30%"}
![](figures/mitey_qrcode.png){.absolute bottom=10 right=10 width="200px"}

::: notes
Software developed to support reproducible analyses and wider application of the methods used in this work.
:::

## Wrapping up

::: nonincremental
### Thank you

-   Jacco Wallinga
-   Mariette Hooiveld

### Funding

This work was financed by the Netherlands Ministry of Health, Welfare and Sport.
:::

## Get in touch!

::::: columns
::: {.column width="60%"}
<i class="fas fa-envelope"></i> kylie.ainslie\@unimelb.edu.au

<i class="fab fa-linkedin"></i> linkedin.com/in/kylieainslie

<i class="fa-brands fa-bluesky"></i> @kylieainslie.bsky.social

<i class="fab fa-github"></i> github.com/kylieainslie

<i class="fas fa-globe"></i> kylieainslie.github.io
:::

::: {.column width="40%"}
![](figures/leon.jpeg){width="100%"}
:::
:::::

```{r, eval = FALSE}
quarto::quarto_render("ITG_presentation.qmd")
```
